ATE324906T1 - Verwendung von chimäres il6-il6r in huntingtonskrankheit - Google Patents

Verwendung von chimäres il6-il6r in huntingtonskrankheit

Info

Publication number
ATE324906T1
ATE324906T1 AT01972039T AT01972039T ATE324906T1 AT E324906 T1 ATE324906 T1 AT E324906T1 AT 01972039 T AT01972039 T AT 01972039T AT 01972039 T AT01972039 T AT 01972039T AT E324906 T1 ATE324906 T1 AT E324906T1
Authority
AT
Austria
Prior art keywords
huntington
disease
il6r
chimeric
derivative
Prior art date
Application number
AT01972039T
Other languages
English (en)
Inventor
Nicole Deglon
Patrick Aebischer
Jean-Charles Bensadoun
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Application granted granted Critical
Publication of ATE324906T1 publication Critical patent/ATE324906T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
AT01972039T 2000-09-14 2001-09-10 Verwendung von chimäres il6-il6r in huntingtonskrankheit ATE324906T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00120045 2000-09-14

Publications (1)

Publication Number Publication Date
ATE324906T1 true ATE324906T1 (de) 2006-06-15

Family

ID=8169836

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01972039T ATE324906T1 (de) 2000-09-14 2001-09-10 Verwendung von chimäres il6-il6r in huntingtonskrankheit

Country Status (13)

Country Link
US (3) US20040057928A1 (de)
EP (1) EP1317273B1 (de)
JP (1) JP5030364B2 (de)
AT (1) ATE324906T1 (de)
AU (2) AU2001291849B2 (de)
CA (1) CA2419954C (de)
CY (1) CY1105116T1 (de)
DE (1) DE60119347T2 (de)
DK (1) DK1317273T3 (de)
ES (1) ES2262680T3 (de)
IL (2) IL154777A0 (de)
PT (1) PT1317273E (de)
WO (1) WO2002022149A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL147412A0 (en) * 2001-12-31 2002-08-14 Yeda Res & Dev The use of il6r/il6 chimera in nerve cell regeneration
WO2004037281A1 (en) * 2002-10-24 2004-05-06 The University Of British Columbia Methods for neuroprotection
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
AU2004247961B2 (en) * 2003-06-12 2010-06-24 Yeda Research & Development Co.Ltd Enhancement of oligodendrocyte differentiation
CA2542353A1 (en) 2003-10-10 2005-04-21 Xencor, Inc. Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
DK2859015T3 (en) 2012-06-08 2018-06-18 Alkermes Inc LIGANDS MODIFIED BY CIRCULAR MODIFICATION AS AGONISTS AND ANTAGONISTS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
IL99803A (en) * 1991-10-20 1997-02-18 Yeda Res & Dev Pharmaceutical compositions comprising interleukin-6 for the treatment of chronic lymphocytic leukemia and B-cell lymphomas
US5792900A (en) * 1991-10-21 1998-08-11 The Trustees Of The University Of Pennsylvania Compositions and methods for producing and using homogenous neuronal cell transplants
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
ATE528405T1 (de) * 1997-12-22 2011-10-15 Oxford Biomedica Ltd Auf dem virus der infektiösen pferdeanämie (eiav) basierende vektoren
JP4859153B2 (ja) * 1999-02-25 2012-01-25 東ソー株式会社 新規神経系細胞分化促進剤
IL130586A0 (en) * 1999-06-21 2000-06-01 Yeda Res & Dev IL6RIL6 chimera for the treatment of demyelinating diseases

Also Published As

Publication number Publication date
EP1317273A1 (de) 2003-06-11
EP1317273B1 (de) 2006-05-03
DE60119347D1 (de) 2006-06-08
AU9184901A (en) 2002-03-26
US20070172454A1 (en) 2007-07-26
IL154777A0 (en) 2003-10-31
PT1317273E (pt) 2006-09-29
CA2419954A1 (en) 2002-03-21
US20100166703A1 (en) 2010-07-01
US8329654B2 (en) 2012-12-11
CA2419954C (en) 2012-01-03
JP5030364B2 (ja) 2012-09-19
CY1105116T1 (el) 2009-11-04
JP2004508409A (ja) 2004-03-18
AU2001291849B2 (en) 2005-11-24
IL154777A (en) 2010-11-30
WO2002022149A1 (en) 2002-03-21
US20040057928A1 (en) 2004-03-25
DK1317273T3 (da) 2006-09-04
DE60119347T2 (de) 2007-02-22
ES2262680T3 (es) 2006-12-01

Similar Documents

Publication Publication Date Title
CY1107248T1 (el) Συντηγμενες πρωτεϊνες
ATE396199T1 (de) Antimikrobielles polypeptid
DOP2002000429A (es) Imidazotriazinas
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
DE69427650D1 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
CY1111912T1 (el) Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
BRPI0414215A (pt) tienopirazóis
DE60108857D1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
BRPI0409359A (pt) análogos quiméricos de somatostatina-dopamina
DE60228878D1 (de) Proteine mit il-6 inhibitorischer wirkung
DK1228097T3 (da) Antimikrobiel aktivitet af den förste kationiske humane lactoferrin-klynge
SE0102147D0 (sv) New methods
BR0012291A (pt) Fenoxifluorpirimidinas
DE60119347D1 (de) Verwendung von chimäres il6-il6r in huntingtonskrankheit
ATE270328T1 (de) Transgene mäuse, die den leukämie inhibierungsfaktor exprimieren können
CY1106363T1 (el) Χρηση του ενepγοποιημενου παραγοντα πηξης vii για την αγωγη των επαγομενων απο θρομβολυτικη θepαπεια μειζονων αιμορραγιων
DK1331940T3 (da) Anvendelse af det lange pentraxin PTX3 til behandling af sygdomme forårsaget af ændret aktivering af vækstfaktoren FGF-2
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
DK1012286T3 (da) Allelvariant af humant STAT3
DK0651648T3 (da) Farmaceutisk præparat indeholdende IL-6. Anvendelse deraf til behandling af konsumptiv trombo-hæmoragisk sygdom
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.
BRPI0412243A (pt) uso de cd164 solúvel em distúrbios inflamatórios e/ou autoimunes
UA94022C2 (ru) Применение ингибитора il-18 для лечения и/или предупреждения алкогольного гепатита
SE0300535D0 (sv) Treatment of burns

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1317273

Country of ref document: EP